Published 3 days ago • loading... • Updated 2 days ago

Health Canada Approves First Generic Weight-Loss Injection

On Monday, Health Canada authorized Svemia, a generic semaglutide injection from Canadian company Apotex, marking the first generic version of Novo Nordisk's Wegovy approved in Canada for weight loss.
Svemia is a generic version of the brand-name drug Wegovy developed by Denmark-based Novo Nordisk. Generic semaglutide products are considered pharmaceutically equivalent, meeting Health Canada's standards for safety, efficacy, and quality.
Health Canada approved Svemia for once-weekly treatment of people 12 and over as a supplement to diet and physical activity. This is the third generic semaglutide authorized, following two earlier approvals for Type 2 diabetes.
Greater availability of generic semaglutide could lead to lower costs for patients and the health-care system. In Canada, generic medications are often priced between 45 and 90 per cent below brand-name counterparts.
Health Canada is currently reviewing six additional submissions for generic semaglutide from other manufacturers. The department expects to make more regulatory decisions in the coming weeks and months.

Insights by Ground AI

46 Articles

First Generic Semaglutide Shot for Weight Loss Gets Green Light in Canada

Health Canada has officially authorized the first generic version of the semaglutide injection that is specifically intended for weight loss. The product from Canadian-based pharmaceutical company Apotex is known as Sevmia and serves as a generic alternative to Wegovy, the brand-name medication developed by Denmark’s Novo Nordisk. “Health Canada authorized the drug after a thorough review of evidence provided by the company demonstrated that the…

2 days ago·New York, United States

Read Full Article